Regeneron's Phase III trial investigated cemdisiran and pozelimab as both monotherapies and in combination in gMG.
New therapies are changing what is possible in generalised myasthenia gravis care, yet unequal access across Europe continues ...
Regeneron (REGN) and Alnylam Pharmaceuticals (ALNY) stock are in focus as myasthenia gravis therapy cemdisiran undergoes U.S. and EU reviews. Read more here.
The FDA has granted Priority Review to cemdisiran, a subcutaneously administered siRNA targeting C5 for anti-AChR antibody-positive generalized myasthenia gravis.
Meron siyang myasthenia gravis na ayon sa mayoclinic.com ay walang gamot – Myasthenia gravis is a condition that happens when ...
Investor's Business Daily on MSN
TG Therapeutics stock is on a hot streak: Why it's up 79% and climbing
TG Therapeutics stock is on an absolute rampage, climbing 79% in roughly the first six months of the year, as the biotech takes on Roche.
James F. Howard Jr., MD, discusses addressing long-standing gaps in seronegative disease care with efgartigimod.
Recent announcements from TG Therapeutics have buoyed optimism on the long-term potential of its Briumvi drug.
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Middle aged woman dressed in pink showing strength and smiling in a park. Fight against ...
As vaccination rates decline, biotech companies see a potential new market for measles drugs. By Teddy Rosenbluth When Dawid Zyla started studying measles in 2020 at the La Jolla Institute for ...
Modern cancer treatment is entering a new era. Scientists are developing medicines that are far more precise than traditional chemotherapy, offering patients new hope and better outcomes. Among the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results